Therapeutic adherence and coping strategies in patients with multiple sclerosis: An observational study.
Journal
Medicine
ISSN: 1536-5964
Titre abrégé: Medicine (Baltimore)
Pays: United States
ID NLM: 2985248R
Informations de publication
Date de publication:
Jul 2019
Jul 2019
Historique:
entrez:
24
7
2019
pubmed:
25
7
2019
medline:
2
8
2019
Statut:
ppublish
Résumé
Multiple sclerosis (MS) is a chronic demyelinating autoimmune disorder affecting the central nervous system and targets the myelin sheaths around nerves. Local problem: Medical advances have enabled patients to lead a better quality of life (QoL) than before. However, because of its chronicity and unpredictability, it remains a very challenging disease for both patients and their families, as it involves the continued use of medication to slow down progression. The aim of this study is to assess drug adherence in patients with MS. In particular, we will examine how the way drugs are administered (oral or injective) affects compliance with therapy, including the correlation with coping strategies and the QoL of each patient.We enrolled 88 patients with MS, divided into 2 groups according to therapy (injective or oral). The Morisky Medication Adherence scale was administered to evaluate adherence to treatment, the MS QoL 54 to estimate mental and physical health, and Brief coping orientation to problems experienced Inventory for coping strategies.The results showed that in both groups the patients showed a good therapeutic alliance and trust in treatment. In particular, a correlation has been found between therapeutic adherence, adaptive coping strategies, and mental health when drug therapy is administered by injection. In conclusion, this result suggests that for patients receiving injection treatment to have greater adherence to therapy, appropriate coping strategies and good mental health must be developed in order for patients receiving injection therapy to have greater adherence to therapy; they need to develop appropriate coping strategies and good mental health to address this mode of administration successfully.
Identifiants
pubmed: 31335734
doi: 10.1097/MD.0000000000016532
pii: 00005792-201907190-00069
pmc: PMC6709257
doi:
Substances chimiques
Immunologic Factors
0
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
e16532Références
Drugs. 2010 Sep 10;70(13):1677-91
pubmed: 20731475
IEEE Trans Image Process. 2013 Jul;22(7):2723-36
pubmed: 23568507
Brain. 1989 Feb;112 ( Pt 1):133-46
pubmed: 2917275
J Manag Care Pharm. 2013 Jan-Feb;19(1 Suppl A):S24-40
pubmed: 23383731
J Clin Hypertens (Greenwich). 2008 May;10(5):348-54
pubmed: 18453793
Adv Ther. 2011 Jan;28(1):51-61
pubmed: 21153000
Clin Neuropsychol. 2002 Aug;16(3):341-55
pubmed: 12607147
J Behav Med. 2010 Jun;33(3):219-27
pubmed: 20127401
Mult Scler. 2012 Jul;18(7):932-46
pubmed: 22249762
J Neurol Sci. 2007 Aug 15;259(1-2):104-8
pubmed: 17376486
Prim Care. 2012 Dec;39(4):649-60
pubmed: 23148958
Qual Life Res. 1995 Jun;4(3):187-206
pubmed: 7613530
Int J Behav Med. 1997;4(1):92-100
pubmed: 16250744
J Med Econ. 2014 Oct;17(10):696-707
pubmed: 25019581
World J Clin Cases. 2015 Jul 16;3(7):545-55
pubmed: 26244148
Eur Neurol. 2006;56(2):78-105
pubmed: 16966832
J Neurosci Nurs. 2010 Oct;42(5 Suppl):S5-9
pubmed: 21049828
IEEE J Biomed Health Inform. 2019 Mar;23(2):703-713
pubmed: 29994054
Neurologia. 2015 May;30(4):214-22
pubmed: 24484756
Int Rev Psychiatry. 2010;22(1):2-13
pubmed: 20233110
J Neurol Neurosurg Psychiatry. 1999 Aug;67(2):158-62
pubmed: 10406981
J Clin Exp Neuropsychol. 2016 Dec;38(10):1158-67
pubmed: 27410680
CNS Drugs. 2009;23(6):453-62
pubmed: 19480465
Clin Drug Investig. 2010;30(2):89-100
pubmed: 20067327